Infant Bacterial Therapeutics

52.50 SEK

-1.87 %

Less than 1K followers

IBT B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-1.87 %
+8.92 %
+12.90 %
+3.96 %
-13.79 %
+3.96 %
+9.38 %
-48.33 %
-10.20 %

Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2011 and is headquartered in Stockholm, Sweden.

Read more
Market cap
707.25M SEK
Turnover
368.69K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/5
2026

Interim report Q1'26

7/5
2026

General meeting '26

26/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.